Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791550 | 1.00 | PTPN1 (0.61) | PTPN1SMN1; SMN2ACKR3OPRM1OPRK1 | |
| SCHEMBL4582840 | 0.86 | PTPN1 (0.63) | PTPN1SMN1; SMN2ACKR3OPRM1OPRK1 | |
| SCHEMBL16594594 | 0.85 | PTPN1 (0.56) | PTPN1SMN1; SMN2ACKR3OPRM1OPRK1 | |
| SCHEMBL3066347 | 0.85 | ALDH1A1 (0.61) | SMN1; SMN2MEN1KMT2AMAPTTSHR | |
| SCHEMBL4808309 | 0.84 | PTPN1 (0.61) | PTPN1ACKR3OPRM1OPRK1MEN1 | |
| SCHEMBL2065774 | 0.84 | PTPN1 (0.61) | PTPN1SMN1; SMN2ACKR3OPRM1OPRK1 | |
| SCHEMBL4631880 | 0.84 | PTPN1 (0.57) | PTPN1ACKR3OPRM1OPRK1MEN1 | |
| SCHEMBL4865028 | 0.84 | PTPN1 (0.68) | PTPN1ACKR3OPRM1OPRK1MEN1 | |
| SCHEMBL7462472 | 0.83 | PTPN1 (0.60) | PTPN1SMN1; SMN2ACKR3OPRM1OPRK1 | |
| SCHEMBL27723504 | 0.82 | PTPN1 (0.59) | PTPN1SMN1; SMN2ACKR3OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486258-B2 | Compounds and methods for regulating insulin secretion | THE BROAD INSTITUTE, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4164622-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | Icahn School of Medicine at Mount Sinai (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11555031-B2 | Compounds and methods for regulating insulin secretion | THE BROAD INSTITUTE, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-3601326-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | The Broad Institute, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175324-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-1727544-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | Sanofi-Aventis (FR) | 2006-12-06 | — | — | EP | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| WO-2005099703-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| CN-1310169-A | Anils with nitric oxide synzyme inhibiting function | SHUGAI SEIYAKU K K (JP) | 2001-08-29 | — | — | CN | disclosed |
| CN-1172473-A | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | IAPP, GPR119, PNLIP | PTPN1 2335/4885SMN1; SMN2 4513/4885ACKR3 2998/4885 |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | PTPN1 2922/4885SMN1; SMN2 4270/4885ACKR3 2478/4885 |
| US-11555031-B2 | Compounds and methods for regulating insulin secretion | IAPP, GPR119, INSR | PTPN1 2028/4885SMN1; SMN2 4326/4885ACKR3 3564/4885 |
| US-12486258-B2 | Compounds and methods for regulating insulin secretion | IAPP, GPR119, PNLIP | PTPN1 2335/4885SMN1; SMN2 4513/4885ACKR3 2998/4885 |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | PTPN1 2893/4885SMN1; SMN2 2906/4885ACKR3 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.